Edwards Net Receivables vs Capital Surpluse Analysis

EW Stock

USD 71.27 0.79 1.12%

Edwards Lifesciences financial indicator trend analysis is much more than just examining Edwards Lifesciences Corp latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edwards Lifesciences Corp is a good investment. Please check the relationship between Edwards Lifesciences Net Receivables and its Capital Surpluse accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

Net Receivables vs Capital Surpluse

Net Receivables vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edwards Lifesciences Corp Net Receivables account and Capital Surpluse. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Edwards Lifesciences' Net Receivables and Capital Surpluse is 0.84. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Edwards Lifesciences Corp, assuming nothing else is changed. The correlation between historical values of Edwards Lifesciences' Net Receivables and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Edwards Lifesciences Corp are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Receivables i.e., Edwards Lifesciences' Net Receivables and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Receivables

Capital Surpluse

Most indicators from Edwards Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

At this time, Edwards Lifesciences' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 0.36 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 169.1 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	4.0B	4.3B	4.6B	4.9B
Total Revenue	5.2B	5.4B	6.0B	6.3B

Gross Profit Total Revenue

Edwards Lifesciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Long Term Debt Total	Other Liab	Net Debt	Accounts Payable	Cash	Other Assets	Long Term Debt
Total Assets		0.68	0.88	0.99	0.97	0.92	0.99	0.8	0.81	0.97	0.7	-0.91	0.72	0.96	0.96	-0.63	0.76	0.94	0.96	0.48	0.93	-0.68	0.73	0.85	0.81	0.4
Other Current Liab	0.68		0.43	0.72	0.72	0.78	0.68	0.66	0.45	0.71	0.29	-0.67	0.39	0.72	0.77	-0.75	0.35	0.74	0.65	0.05	0.54	-0.48	0.4	0.45	0.65	0.31
Total Current Liabilities	0.88	0.43		0.82	0.8	0.69	0.87	0.65	0.74	0.85	0.74	-0.8	0.68	0.85	0.77	-0.34	0.81	0.77	0.85	0.61	0.91	-0.47	0.61	0.77	0.64	0.25
Total Stockholder Equity	0.99	0.72	0.82		0.99	0.95	0.98	0.84	0.75	0.97	0.66	-0.9	0.63	0.97	0.98	-0.69	0.67	0.97	0.94	0.37	0.87	-0.68	0.75	0.79	0.81	0.34
Property Plant And Equipment Net	0.97	0.72	0.8	0.99		0.93	0.98	0.8	0.71	0.97	0.67	-0.86	0.64	0.96	0.98	-0.66	0.67	0.96	0.91	0.32	0.87	-0.7	0.78	0.77	0.84	0.31
Retained Earnings	0.92	0.78	0.69	0.95	0.93		0.89	0.93	0.73	0.93	0.45	-0.87	0.52	0.93	0.96	-0.87	0.53	0.96	0.91	0.27	0.73	-0.66	0.58	0.73	0.79	0.35
Non Current Assets Total	0.99	0.68	0.87	0.98	0.98	0.89		0.77	0.72	0.95	0.76	-0.87	0.7	0.94	0.95	-0.58	0.75	0.92	0.9	0.46	0.92	-0.61	0.8	0.79	0.79	0.36
Non Currrent Assets Other	0.8	0.66	0.65	0.84	0.8	0.93	0.77		0.61	0.83	0.33	-0.8	0.29	0.88	0.84	-0.86	0.35	0.91	0.81	0.19	0.58	-0.54	0.44	0.62	0.74	0.16
Cash And Short Term Investments	0.81	0.45	0.74	0.75	0.71	0.73	0.72	0.61		0.76	0.42	-0.83	0.78	0.72	0.74	-0.55	0.75	0.68	0.92	0.63	0.8	-0.69	0.32	0.93	0.63	0.61
Net Receivables	0.97	0.71	0.85	0.97	0.97	0.93	0.95	0.83	0.76		0.61	-0.88	0.63	0.98	0.95	-0.67	0.68	0.96	0.95	0.32	0.87	-0.75	0.67	0.82	0.79	0.28
Good Will	0.7	0.29	0.74	0.66	0.67	0.45	0.76	0.33	0.42	0.61		-0.52	0.72	0.63	0.57	-0.04	0.81	0.55	0.56	0.6	0.79	-0.35	0.88	0.59	0.53	0.37
Common Stock Shares Outstanding	-0.91	-0.67	-0.8	-0.9	-0.86	-0.87	-0.87	-0.8	-0.83	-0.88	-0.52		-0.59	-0.9	-0.88	0.62	-0.59	-0.88	-0.93	-0.48	-0.83	0.62	-0.52	-0.85	-0.75	-0.46
Non Current Liabilities Total	0.72	0.39	0.68	0.63	0.64	0.52	0.7	0.29	0.78	0.63	0.72	-0.59		0.57	0.59	-0.27	0.96	0.48	0.72	0.76	0.85	-0.56	0.54	0.82	0.59	0.74
Inventory	0.96	0.72	0.85	0.97	0.96	0.93	0.94	0.88	0.72	0.98	0.63	-0.9	0.57		0.96	-0.68	0.63	0.98	0.93	0.33	0.85	-0.69	0.69	0.79	0.84	0.26
Other Current Assets	0.96	0.77	0.77	0.98	0.98	0.96	0.95	0.84	0.74	0.95	0.57	-0.88	0.59	0.96		-0.74	0.62	0.97	0.93	0.3	0.83	-0.69	0.7	0.76	0.85	0.3
Other Stockholder Equity	-0.63	-0.75	-0.34	-0.69	-0.66	-0.87	-0.58	-0.86	-0.55	-0.67	-0.04	0.62	-0.27	-0.68	-0.74		-0.22	-0.74	-0.67	-0.05	-0.37	0.51	-0.23	-0.48	-0.64	-0.3
Total Liab	0.76	0.35	0.81	0.67	0.67	0.53	0.75	0.35	0.75	0.68	0.81	-0.59	0.96	0.63	0.62	-0.22		0.53	0.74	0.78	0.88	-0.5	0.61	0.79	0.58	0.6
Property Plant And Equipment Gross	0.94	0.74	0.77	0.97	0.96	0.96	0.92	0.91	0.68	0.96	0.55	-0.88	0.48	0.98	0.97	-0.74	0.53		0.91	0.23	0.78	-0.69	0.68	0.74	0.82	0.22
Total Current Assets	0.96	0.65	0.85	0.94	0.91	0.91	0.9	0.81	0.92	0.95	0.56	-0.93	0.72	0.93	0.93	-0.67	0.74	0.91		0.48	0.89	-0.76	0.55	0.92	0.79	0.44
Short Long Term Debt Total	0.48	0.05	0.61	0.37	0.32	0.27	0.46	0.19	0.63	0.32	0.6	-0.48	0.76	0.33	0.3	-0.05	0.78	0.23	0.48		0.61	-0.06	0.31	0.61	0.32	0.74
Other Liab	0.93	0.54	0.91	0.87	0.87	0.73	0.92	0.58	0.8	0.87	0.79	-0.83	0.85	0.85	0.83	-0.37	0.88	0.78	0.89	0.61		-0.67	0.71	0.89	0.8	0.44
Net Debt	-0.68	-0.48	-0.47	-0.68	-0.7	-0.66	-0.61	-0.54	-0.69	-0.75	-0.35	0.62	-0.56	-0.69	-0.69	0.51	-0.5	-0.69	-0.76	-0.06	-0.67		-0.44	-0.8	-0.68	-0.26
Accounts Payable	0.73	0.4	0.61	0.75	0.78	0.58	0.8	0.44	0.32	0.67	0.88	-0.52	0.54	0.69	0.7	-0.23	0.61	0.68	0.55	0.31	0.71	-0.44		0.51	0.62	0.21
Cash	0.85	0.45	0.77	0.79	0.77	0.73	0.79	0.62	0.93	0.82	0.59	-0.85	0.82	0.79	0.76	-0.48	0.79	0.74	0.92	0.61	0.89	-0.8	0.51		0.75	0.6
Other Assets	0.81	0.65	0.64	0.81	0.84	0.79	0.79	0.74	0.63	0.79	0.53	-0.75	0.59	0.84	0.85	-0.64	0.58	0.82	0.79	0.32	0.8	-0.68	0.62	0.75		0.31
Long Term Debt	0.4	0.31	0.25	0.34	0.31	0.35	0.36	0.16	0.61	0.28	0.37	-0.46	0.74	0.26	0.3	-0.3	0.6	0.22	0.44	0.74	0.44	-0.26	0.21	0.6	0.31

Click cells to compare fundamentals

Edwards Lifesciences Account Relationship Matchups

Edwards Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.5B	7.2B	8.5B	8.3B	9.4B	9.8B
Other Current Liab	6.4M	574.7M	677.3M	673.3M	821.9M	863.0M
Total Current Liabilities	902.4M	893.9M	1.0B	1.0B	1.2B	1.3B
Total Stockholder Equity	4.1B	4.6B	5.8B	5.8B	6.7B	7.0B
Property Plant And Equipment Net	1.1B	1.5B	1.6B	1.7B	1.8B	1.9B
Retained Earnings	3.7B	4.6B	6.1B	7.6B	9.0B	9.4B
Non Current Assets Total	3.5B	4.1B	5.3B	5.2B	5.3B	5.6B
Non Currrent Assets Other	101.8M	119.6M	110.8M	299.1M	463.7M	486.9M
Cash And Short Term Investments	1.5B	1.4B	1.5B	1.2B	1.6B	1.7B
Net Receivables	599.1M	602.8M	664.9M	699.1M	836.9M	878.7M
Good Will	1.2B	1.2B	1.2B	1.2B	1.3B	688.6M
Common Stock Shares Outstanding	636.6M	631.9M	631.2M	624.2M	609.4M	550.8M
Liabilities And Stockholders Equity	6.5B	7.2B	8.5B	8.3B	9.4B	9.8B
Non Current Liabilities Total	1.4B	1.8B	1.6B	1.5B	1.4B	800.7M
Inventory	640.9M	802.3M	726.7M	875.5M	1.2B	1.2B
Other Current Assets	168M	283.3M	322.3M	305.9M	386.1M	405.4M
Other Stockholder Equity	344.6M	(466M)	(716.5M)	(2.2B)	(2.8B)	(2.6B)
Total Liab	2.3B	2.7B	2.7B	2.5B	2.6B	1.4B
Property Plant And Equipment Gross	1.1B	1.5B	1.6B	1.7B	2.7B	2.8B
Total Current Assets	3.0B	3.1B	3.2B	3.1B	4.0B	4.2B
Accumulated Other Comprehensive Income	(156M)	(161.1M)	(157.7M)	(254.9M)	(242.8M)	(230.7M)
Short Long Term Debt Total	593.8M	678.8M	694.9M	690.3M	691.3M	486.4M
Other Liab	784.1M	1.1B	969.6M	797.6M	917.2M	963.1M
Net Debt	(500.3M)	(488.3M)	(172.5M)	(77.7M)	(449.1M)	(426.6M)
Accounts Payable	180.4M	196.5M	204.5M	201.9M	201.4M	139.5M
Cash	1.2B	1.2B	862.8M	769M	1.1B	1.2B
Other Assets	274M	1.2B	357.5M	783.1M	900.6M	945.6M
Long Term Debt	594.4M	595M	595.7M	596.3M	597M	425.6M
Common Stock Total Equity	218.1M	636.4M	642M	646.3M	743.2M	780.4M
Short Term Debt	0.0	25.5M	54.4M	51M	49.8M	47.3M
Intangible Assets	336.5M	331.4M	323.6M	285.2M	428.4M	449.8M
Common Stock	218.1M	636.4M	642M	646.3M	650.5M	683.0M
Property Plant Equipment	1.1B	1.4B	1.6B	1.7B	2.0B	2.1B
Treasury Stock	(1.0B)	(1.3B)	(1.9B)	(2.4B)	(2.2B)	(2.1B)
Short Term Investments	337.8M	219.4M	604M	446.3M	500.5M	382.6M
Net Tangible Assets	2.9B	3.4B	4.3B	4.4B	5.0B	5.3B
Retained Earnings Total Equity	3.7B	4.6B	6.1B	7.6B	8.7B	9.2B
Capital Surpluse	1.6B	1.4B	1.7B	2.0B	2.3B	1.2B
Long Term Investments	585.5M	801.6M	1.8B	1.2B	583.9M	582.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edwards Net Receivables vs Capital Surpluse Analysis

Net Receivables vs Capital Surpluse

Net Receivables vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Net Receivables

Capital Surpluse

Edwards Lifesciences fundamental ratios Correlations

Edwards Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edwards Lifesciences fundamental ratios Accounts

Also Currently Popular

Additional Tools for Edwards Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.98	Total Stockholder Equity
Other Current Assets	+ 0.98	Total Stockholder Equity
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net

Total Current Assets	- 0.93	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.91	Total Assets
Inventory	- 0.9	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.9	Total Stockholder Equity
Property Plant And Equipment Gross	- 0.88	Common Stock Shares Outstanding
Other Current Assets	- 0.88	Common Stock Shares Outstanding